Indaptus Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Indaptus Therapeutics wird ein Gewinn- und Umsatzwachstum von 16.4% bzw. 90.1% pro Jahr prognostiziert, während der Gewinn pro Aktie um 42.5% pro Jahr wachsen soll.

Wichtige Informationen

16.4%

Wachstumsrate der Gewinne

42.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	90.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	12 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

Mar 27

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

Aug 15

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Aug 08

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

Sep 29

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:INDP - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-22	N/A	N/A	1
12/31/2025	N/A	-21	N/A	N/A	2
12/31/2024	N/A	-15	N/A	N/A	2
9/30/2024	N/A	-15	-12	-12	N/A
6/30/2024	N/A	-16	-13	-13	N/A
3/31/2024	N/A	-15	-12	-12	N/A
12/31/2023	N/A	-15	-13	-13	N/A
9/30/2023	N/A	-15	-13	-13	N/A
6/30/2023	N/A	-15	-14	-14	N/A
3/31/2023	N/A	-15	-15	-15	N/A
12/31/2022	N/A	-14	-13	-13	N/A
9/30/2022	N/A	-14	-14	-14	N/A
6/30/2022	N/A	-14	-15	-15	N/A
3/31/2022	N/A	-10	-14	-14	N/A
12/31/2021	N/A	-8	-11	-11	N/A
9/30/2021	N/A	-5	-9	-9	N/A
6/30/2021	N/A	-3	-4	-4	N/A
3/31/2021	N/A	-4	-4	-4	N/A
12/31/2020	N/A	-4	-3	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: INDP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: INDP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: INDP wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: INDP wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: INDP wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von INDP in 3 Jahren voraussichtlich hoch sein wird

Indaptus Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 15% to US$15.00

Price target decreased to US$11.00

Recent updates

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.134995 million.

New major risk - Financial position

Indaptus Therapeutics, Inc. Presents Clinical Data on Decoy20 at SITC 2024 Annual Meeting

Indaptus Therapeutics, Inc. Provides Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

New minor risk - Shareholder dilution

Indaptus Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $3.000003 million.

Indaptus Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.3 million.

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

New major risk - Financial position

New minor risk - Share price stability

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial

Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20

Indaptus Therapeutics, Inc. Doses First Patient in Second Cohort of Single Dose Ranging Study of Decoy20

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Deliver On Growth Plans?

Indaptus Therapeutics, Inc. Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Indaptus Therapeutics, Inc. Appoints Roger Waltzman as Its Chief Medical Officer, Effective August 7, 2023

Price target increased by 15% to US$15.00

Indaptus Therapeutics, Inc. Names Robert Martell, M.D., Ph.D. to Its Board of Directors

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Price target decreased to US$11.00

High number of new and inexperienced directors

Indaptus Therapeutics GAAP EPS of -$0.46 beats by $0.45

Indaptus Therapeutics, Inc., Annual General Meeting, Sep 29, 2022

CEO & Director recently bought US$52k worth of stock

Indaptus Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

High number of new and inexperienced directors

High number of new and inexperienced directors

CEO & Director recently bought US$65k worth of stock

Insider recently bought US$691k worth of stock

Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications

CEO & Director recently bought US$84k worth of stock

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken